Deferoxamine
Iron chelating agentsIron ChelatorIron Chelating ActivityUnknown Physiological EffectUS-FDASourced from openFDA
GET
/api/v1/drug/deferoxamineMechanism of action
Sourced from openFDAMechanism-of-action class: Iron Chelating Activity.
Approval history
Sourced from openFDA- Apr 1, 1968NDANDA016267Mitem Pharma
- Mar 17, 2004ANDAANDA076019Hospira
- Sep 15, 2009ANDAANDA078718Fresenius Kabi Usa
- Sep 29, 2017ANDAANDA207384Gland
FAERS reports
Reference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. Counts reflect reporting volume — how often a reaction was reported, not how often it occurs. For decision-grade use, consult openFDA and the FAERS Public Dashboard directly.
2,100 total reports matchedLatest report Share = reports listing the reaction ÷ total matched reports. Rows can sum to >100% because a single report often lists multiple reactions.
- 1Serum Ferritin Increased1688.0%
- 2Pyrexia1446.9%
- 3Drug Ineffective1426.8%
- 4Off Label Use1266.0%
- 5Haemoglobin Decreased1205.7%
- 6Diarrhoea1155.5%
- 7Vomiting1095.2%
- 8Death1034.9%
- 9Nausea994.7%
- 10Fatigue934.4%
- 11Dyspnoea924.4%
- 12Blood Creatinine Increased803.8%
- 13Abdominal Pain793.8%
- 14Anaemia753.6%
- 15Pain733.5%
Literature
Recent PubMed references pinned to Deferoxamine as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.
- Deferoxamine Improves Radiation-Induced Peripheral Neuropathy.Journal of cellular and molecular medicine · 2026 · Lavin CV, Fazilat AZ, Kendig CB, et al.PMID 42252579DOI 10.1111/jcmm.71227
- Deferoxamine Modulates Corneal Endothelial Cell Biological Properties Associated with Increased VEGF Expression.Medicina (Kaunas, Lithuania) · 2026 · Brunner BS, Emesz P, Luft N, et al.PMID 42195061DOI 10.3390/medicina62050808
- Deferoxamine alleviates T-2 toxin-induced articular chondrocyte ferroptosis via the Nrf2/xCT/GPX4 axis: Implications for Kashin-Beck disease pathology.Toxicon : official journal of the International Society on Toxinology · 2026 · Ren YM, Hou WY, Pan Y, et al.PMID 42103195DOI 10.1016/j.toxicon.2026.109146
- Deferoxamine attenuates early brain injury after subarachnoid hemorrhage by inhibiting ferroptosis and preserving mitochondrial function and oxidative phosphorylation via Nrf2 signaling.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association · 2026 · Liu G, Shan W, Zhang Z, et al.PMID 42049118DOI 10.1016/j.jstrokecerebrovasdis.2026.108644
- Combined targeting of iron overload and BLVRA synergistically attenuates reactive astrocytes after subarachnoid hemorrhage.Experimental neurology · 2026 · Zheng Y, Lang D, Li Z, et al.PMID 42031091DOI 10.1016/j.expneurol.2026.115791
- Deferoxamine attenuates bone cancer pain via modulation of the RIG-I/CCL5 signaling pathway in rats.Neuropharmacology · 2026 · Hang LH, Ju JJ, He M, et al.PMID 41999973DOI 10.1016/j.neuropharm.2026.110974
- Se/S co-doped onion-derived CDs synergistically treat AKI by alleviating oxidative stress and enhancing iron chelation.Journal of colloid and interface science · 2026 · Liu Z, Liu X, He L, et al.PMID 41950563DOI 10.1016/j.jcis.2026.140422
- Deferoxamine mitigates neuronal loss following spinal cord injury via ferroptosis inhibition and Nrf2/HO‑1 pathway activation.International journal of molecular medicine · 2026 · Ma Z, Zhang X, Liu T, et al.PMID 41891961DOI 10.3892/ijmm.2026.5808
Clinical trials
The 10 most recently updated of 75 ClinicalTrials.gov registrations naming Deferoxamine as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.
- Deferoxamine for the Prevention of Cardiac Surgery-Associated Acute Kidney InjuryActive not recruiting · Phase 2 · Interventional · 320 enrolled · Brigham and Women's HospitalNCT04633889updated 2026-06-12
- Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal LeukoencephalopathyRecruiting · Phase 1 · Interventional · 15 enrolled · National Institute of Neurological Disorders and Stroke (NINDS)NCT05849467updated 2026-06-05
- Combination of Thalidomide and Hydroxyuria in Transfusion Dependent ThalasemmiaCompleted · Phase 2 · Interventional · 100 enrolled · Pakistan Blood and Marrow Transplant (PBMT) GroupNCT07292259updated 2026-05-05
- A Study of Deferoxamine (DFO) in People With Leptomeningeal MetastasisRecruiting · Phase 1 · Interventional · 35 enrolled · Memorial Sloan Kettering Cancer CenterNCT05184816updated 2026-03-27
- Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain TumorsRecruiting · Phase 1 · Interventional · 20 enrolled · Jonsson Comprehensive Cancer CenterNCT06650163updated 2026-02-05
- Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)Recruiting · Phase 1 · Interventional · 10 enrolled · City of Hope Medical CenterNCT05371132updated 2026-01-28
- Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)Recruiting · Phase 2 · Interventional · 120 enrolled · Aditya S. Pandey, MDNCT04566991updated 2025-11-28
- Early Screening and Treatment of Heart Complication in Sickle Cell DiseaseRecruiting · Phase 2 · Interventional · 100 enrolled · Inova Health Care ServicesNCT07023666updated 2025-10-14
- Synergistic Minimally Invasive Surgery and Deferoxamine in ICHNot yet recruiting · Phase 2 · Phase 3 · Interventional · 240 enrolled · University of Illinois at ChicagoNCT07162363updated 2025-10-10
- A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung CancerRecruiting · Phase 1 · Interventional · 5 enrolled · Memorial Sloan Kettering Cancer CenterNCT06863233updated 2025-08-12
Frequently asked questions
- How does Deferoxamine work?
- Mechanism-of-action class: Iron Chelating Activity.
- What class of drug is Deferoxamine?
- Deferoxamine is classified as Iron chelating agents, Iron Chelator, Iron Chelating Activity, Unknown Physiological Effect.
- What are the brand names for Deferoxamine?
- Deferoxamine is marketed under brand names including Desferal.
Note. Data for
deferoxamine is illustrative MVP content compiled from public sources. pharmacopeia is for educational and informational use only and is not a substitute for professional medical advice.